The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 11, 2025

Filed:

Nov. 07, 2019
Applicants:

The Regents of the University of California, Oakland, CA (US);

The Trustees of Princeton University, Princeton, NJ (US);

The Simons Foundation, Inc., New York, NY (US);

Inventors:

Wendell A. Lim, San Francisco, CA (US);

Olga G. Troyanskaya, Princeton, NJ (US);

Benjamin Vandersluis, New York, NY (US);

Ruth Dannenfelser, Princeton, NJ (US);

Assignees:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/40 (2006.01);
U.S. Cl.
CPC ...
C07K 16/3015 (2013.01); A61K 39/00 (2013.01); A61K 39/0011 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4202 (2025.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 16/28 (2013.01); C07K 16/40 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/47 (2023.05); A61K 2239/49 (2023.05); A61K 2239/54 (2023.05); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2319/00 (2013.01);
Abstract

The present disclosure provides immune cells genetically modified to produce two antigentriggered polypeptides, each recognizing a different cell surface antigen, wherein the two different cell surface antigens employed are selected from those pairs described herein. The present disclosure further provides systems comprising two antigen-triggered polypeptides (or nucleic acids encoding same), each recognizing a different cell surface antigen, wherein the two different cell surface antigens employed are selected from those pairs described herein. Also provided are method of killing a target cancer cell, using the described genetically modified immune cells and/or systems. The present disclosure also provides poly specific-immune inducing polypeptides including first and second antigen binding domains specific for first and second antigens, respectively, present on the surface of a target cancer cell.


Find Patent Forward Citations

Loading…